Beyond Rogue Cells: How Glioblastoma Recruits an Ecosystem to Survive
Overview:
Most people think that cancer is just some cells gone rogue. The truth is more complicated
than that. Hanahan introduces the framework that cancer cells themselves do not define
cancer biology. Rather, what defines it is the recruitment of other cells to acquire the
hallmarks of cancer. The hallmarks of cancer act as the main mechanisms that tumors
acquire (1). Glioblastoma Multiforme (GBM) builds overlapping interactions between these
mechanisms.
GBM is highly aggressive. Recurrence occurs in 75-90% of cases, demonstrating just
reliably this cancer builds its own safety nets (2). As Hanahan and Pouyan et al describe,
cancer, especially GBM, manipulates various factors to ensure its own survival (1, 2). Thus,
targeting one factor is not enough. Rather, GBM should be attacked with methods that
target multiple pathways and mechanisms. GBM is not the result of a single regulatory
failure, it is the result of a complex web of interacting factors that serve to aid its survival
and growth.
Metabolic Reprogramming
All cells need energy to grow and proliferate. Cancer cells require the same energy. The
difference between a normal cell and a cancer cell is how they get their fuel. While a
normal cell goes through oxidative phosphorylation in mitochondria and sometimes
glycolysis, cancer cells could be considered metabolic hybrids (1). Normal cells rely on
oxidative phosphorylation, but cancer cells use whatever method they need to get their fuel.
Cancer cells can rely on different amino acids, particularly glutamine, to fuel themselves.
Additionally, they can perform autophagy and other modes of cell recycling (1). Non-
cellular factors can influence cell proliferation. Things such as the tumor microenvironment’s acidity, the oxygen levels, some amino acids, and secretions all play a part in whether the cancer cell can keep dividing (1).
GBM utilizes metabolic reprogramming to fuel its spread. It must be incredibly efficient at
doing so. In addition, GBM grows in microscopic projections, making it almost impossible
to achieve a proper surgical resection (3). Metabolic reprogramming fuels GBM, and the
resulting growth contributes to the 5-year survival rate of 7.2% (3).
Oncogenic Signaling
The safety nets of GBM are reinforced by a chaotic signaling environment. Some key
players are Pak2, TET enzymes, and p53. These factors are often associated with poor
outcomes.
Pak2
Pak2 is an enzyme that regulates cell death, cell migration, and gene expression. It is part of
a group of enzymes that control gene transcription, and cellular signaling through
phosphorylation. The enzyme’s length determines its function. Additionally, the agent used
to divide Pak2 influences function as well (4). For example, Pak2 controls cell growth by
activating the mitogen-activated protein kinase (MAPK). When MAPK is activated, it helps
regulate cell growth and survival (4). This, along with the regulation of other proteins,
means Pak2 expression is associated with a poor prognosis.
TET Enzymes
Ten-eleven translocation (TET) proteins help transcription factors regulate gene expression
and cell activation (5). TET proteins also manage passive and active forms of DNA
methylation (the process of adding a methyl group). Because these proteins work with gene
expression and DNA methylation, they can regulate cell specification and change a mature
cell into a different type (5). TET deficiency is linked to inflammation, which in turn allows
for the TET deficient cells to expand. These attributes serve to facilitate the growth and
spread of cancers, including glioblastoma.
P53
P53 is a transcription factor with tumor-suppressing functions. However, it’s found in
cancers in its mutated form (6). Under normal physiology, p53 sensitizes tumor cells to
immune responses. Thus, the loss or mutation of p53 makes tumor cells resistant to immune
responses, and in turn, therapies (6). P53 also regulates metabolism. By suppressing
anabolic reactions like glycolysis and promoting aerobic ones, p53 can help limit a tumor
cell’s fuel supply (6). P53 can either help or inhibit treatment, making it a possible target in
therapies.
Conclusion
Glioblastoma, like other cancers, is not an isolated mechanism or group of rogue cells.
From metabolic reprogramming to the various types of oncogenic signaling, glioblastoma
creates various safety nets, allowing it to succeed. As Hanahan’s paper suggests, tumors
recruit and manipulate their environments to create a complex web of support systems.
Because of this, targeting glioblastoma with a single weapon will fail. The 7.2% survival
rate reminds us of this. Thus, the future of glioblastoma treatments lies in multi-faceted
approaches. We must be able to disrupt not just one part of the tumor, but diffuse the
metabolism, the signaling, the growth factors, and the various other factors that contribute
to the tumor. By dismantling the web of safety nets, we can hope to turn the tide against
glioblastoma.
References:
1. Hanahan, D. (2026). Hallmarks of cancer—Then and now, and beyond. Cell,
189(8), 2254–2277. https://doi.org/10.1016/j.cell.2025.12.049
2. Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A.,
Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., Entezari, M.,
Taheriazam, A., Hushmandi, K., & Hashemi, M. (2025). Glioblastoma multiforme:
Insights into pathogenesis, key signaling pathways, and therapeutic strategies.
Molecular Cancer, 24(1), 58. https://doi.org/10.1186/s12943-025-02267-0
3. Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., &
Daldrup-Link, H. E. (2021). Glioblastoma Multiforme (GBM): An overview of
current therapies and mechanisms of resistance. Pharmacological Research, 171,
4. Wu, M., Sarkar, C., & Guo, B. (2024). Regulation of Cancer Metastasis by PAK2.
International Journal of Molecular Sciences, 25(24), 13443.
5. López-Moyado, I. F., Ko, M., Hogan, P. G., & Rao, A. (2024). TET Enzymes in the
Immune System: From DNA Demethylation to Immunotherapy, Inflammation, and
Cancer. Annual Review of Immunology, 42(1), 455–488.
6. Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024). Understanding the complexity of p53
in a new era of tumor suppression. Cancer Cell, 42(6), 946–967.
Assessed and Endorsed by the MedReport Medical Review Board
